MAPT and Alzheimer disease: The superior performance of plasma p-tau217 over plasma p-tau181 and plasma p-tau231 at detecting early AD biochemical signatures and its sensitivity to capture cognitive changes might be attributed to its unique properties observed in in vitro models, such as promoting synaptic decline and the formation of tau-tau interactions at the expense of tau binding to microtubules.37